ADBIOTECH Amends 3 Billion Won CB Issuance Terms: Conversion Price Lowered to 1,992 Won and Payor Changed, Increasing Dilution Burden


  • ADBIOTECH filed an amendment on July 21, 2026, to its initial decision to issue 3 billion won in 10th-series convertible bonds. The payor was changed from Awesome Investment Association to K-Polaris Investment Association, and the payment date was postponed to August 19.
  • The key change is the conversion price reduced from 2,264 won to 1,992 won, approximately 12% lower, increasing the number of shares to be issued from 1.32 million to 1.50 million. Consequently, the new shares ratio to outstanding shares rose from 6.31% to 7.11%.
  • Including existing outstanding convertible bonds, the total potential dilution ratio reaches 38.98%, posing significant risk to existing shareholders. The proceeds are designated for acquisition of other companies' securities, but the specific target remains undisclosed.
  • K-Polaris Investment Association is a small investment union with four partners and no publicly available financial statements, raising transparency concerns. No treasury stock acquisition or dividend policy has been disclosed.
  • [AI Summary]This amendment further reduces the conversion price and changes the payor without clarifying the use of funds. With cumulative dilution approaching 39%, this CB issuance adds long-term overhang pressure on the stock price. If the funds are not deployed productively, existing shareholder value could be severely undermined.

KOSDAQ Filing Information


  • [Correction of Description] Report on Major Matters (Decision on Issuance of Convertible Bonds)
  • Company: ADBIOTECH (179530)
  • Submission: ADBIOTECH Co.,Ltd.

  • Shares: 26,950,299
  • Price: 1,822 KRW
  • Market Cap: 49.1 B KRW